Jump Financial LLC Makes New $1.20 Million Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Jump Financial LLC acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 50,911 shares of the company's stock, valued at approximately $1,199,000. Jump Financial LLC owned approximately 0.05% of Dyne Therapeutics at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in shares of Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock valued at $5,532,000 after purchasing an additional 698 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after acquiring an additional 721 shares during the last quarter. KBC Group NV grew its holdings in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after acquiring an additional 978 shares during the period. E Fund Management Co. Ltd. raised its position in shares of Dyne Therapeutics by 11.8% during the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock valued at $279,000 after acquiring an additional 1,249 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Dyne Therapeutics by 11.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company's stock valued at $508,000 after purchasing an additional 2,265 shares during the period. 96.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on DYN. HC Wainwright reaffirmed a "buy" rating and set a $46.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 17th. JPMorgan Chase & Co. lowered their price target on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Royal Bank of Canada reissued an "outperform" rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Scotiabank started coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price for the company. Finally, Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $47.46.

Dyne Therapeutics Stock Down 0.5 %

Shares of NASDAQ DYN traded down $0.05 during mid-day trading on Friday, reaching $11.06. 1,568,408 shares of the company were exchanged, compared to its average volume of 1,531,723. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $47.45. The stock has a market capitalization of $1.26 billion, a P/E ratio of -3.11 and a beta of 1.21. The company's 50-day simple moving average is $10.79 and its 200-day simple moving average is $19.71.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. As a group, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 6,237 shares of company stock valued at $77,760 over the last quarter. 20.77% of the stock is owned by corporate insiders.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.